Premium
Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply
Author(s) -
Talal A. H.,
LaFleur J.,
Hoop R. S.,
Pandya P.,
Martin P.,
Jacobson I. M.,
Han J.,
Korner E. J.
Publication year - 2013
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.12424
Subject(s) - medicine , ribavirin , pegylated interferon , population , hepatitis c , hepatitis c virus , chronic hepatitis , injection drug use , drug , intensive care medicine , psychiatry , immunology , virus , drug injection , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom